<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="review-article" dtd-version="1.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1656846</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2025.1656846</article-id>
<article-version article-version-type="Version of Record" vocab="NISO-RP-8-2008"/>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Mini Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>
<italic>Abhraka Bhasma</italic> (mica based nanomedicine): an ayurvedic herbomineral perspective in breast cancer management</article-title>
<alt-title alt-title-type="left-running-head">Soman Pillai and Karavettekudy Ranjit</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2025.1656846">10.3389/fphar.2025.1656846</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Soman Pillai</surname>
<given-names>Dhanya</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/3117116"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Karavettekudy Ranjit</surname>
<given-names>Amarnath</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/3310299"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role>
</contrib>
</contrib-group>
<aff id="aff1">
<label>1</label>
<institution>Department of Rasashastra and Bhaishajya Kalpana (Pharmaceuticals), Amrita School of Ayurveda, Amritapuri, Amrita Vishwa Vidyapeetham</institution>, <city>Kollam</city>, <state>Kerala</state>, <country country="IN">India</country>
</aff>
<aff id="aff2">
<label>2</label>
<institution>Department of Computer Science and Engineering, Amrita school of Computing, Amritapuri, Amrita Vishwa Vidyapeetham</institution>, <city>Kollam</city>, <state>Kerala</state>, <country country="IN">India</country>
</aff>
<author-notes>
<corresp id="c001">
<label>&#x2a;</label>Correspondence: Dhanya Soman Pillai, <email xlink:href="mailto:dhanyas@ay.amrita.edu">dhanyas@ay.amrita.edu</email>
</corresp>
</author-notes>
<pub-date publication-format="electronic" date-type="pub" iso-8601-date="2025-12-19">
<day>19</day>
<month>12</month>
<year>2025</year>
</pub-date>
<pub-date publication-format="electronic" date-type="collection">
<year>2025</year>
</pub-date>
<volume>16</volume>
<elocation-id>1656846</elocation-id>
<history>
<date date-type="received">
<day>09</day>
<month>07</month>
<year>2025</year>
</date>
<date date-type="rev-recd">
<day>09</day>
<month>11</month>
<year>2025</year>
</date>
<date date-type="accepted">
<day>29</day>
<month>11</month>
<year>2025</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2025 Soman Pillai and Karavettekudy Ranjit.</copyright-statement>
<copyright-year>2025</copyright-year>
<copyright-holder>Soman Pillai and Karavettekudy Ranjit</copyright-holder>
<license>
<ali:license_ref start_date="2025-12-19">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<sec>
<title>Background</title>
<p>Abhraka Bhasma (Mica nanoparticles) is an Ayurvedic herbomineral medicine traditionally used in the management of conditions similar to breast cancer. Its rationale is based on its <italic>Dhatu-Pushtikara</italic> (tissue-nourishing), <italic>Rasayana</italic> (rejuvenating) and <italic>Tridosha</italic>-balancing properties, suggesting its potential for evaluation in integrative oncology.</p>
</sec>
<sec>
<title>Objective</title>
<p>This work aims to examine the therapeutic potential of Mica nanoparticles (<italic>Abhraka Bhasma</italic>) as an alternative medicine in the management of breast cancer.</p>
</sec>
<sec>
<title>Methods (type of evidence)</title>
<p>This mini-review analyses the preclinical and limited clinical evidence supporting <italic>Abhraka Bhasma</italic> (mica nanoparticles) as a potential adjunct in breast cancer management. The mechanistic basis was evaluated from <italic>in vitro</italic> and <italic>in vivo</italic> models.</p>
</sec>
<sec>
<title>Key findings</title>
<p>
<italic>In vitro</italic>: <italic>Abhraka Bhasma</italic> exhibits dose-dependent cytotoxicity, apoptosis, immunomodulatory activity and inhibition of teratoma-formation in different cell lines. <italic>In vivo</italic>: studies support these findings, indicating enhanced DNA repair capacity, reduced genotoxicity, chemopreventive responses, immunostimulatory effects and modulation of oxidative stress.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>The traditional Ayurvedic rationale for <italic>Abhraka Bhasma</italic> correlates with reported preclinical mechanisms. Thus, the ancient wisdom and modern evidence make <italic>Abhraka Bhasma</italic> an important part of integrative oncology, which offers a complementary strategy to improve patient outcomes. Available evidence on <italic>Abhraka Bhasma</italic> in cancer treatment is currently preclinical data (Level 5) and hypothesis generating only. To date, no RCTs or cohort studies (Levels 1&#x2013;3) on the safety and efficacy of <italic>Abhraka Bhasma</italic> as an adjunct in breast cancer treatment have been published. To bridge the gap between traditional use and evidence based clinical application, a structured and systematic research pathway is essential.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Abhraka bhasma</kwd>
<kwd>breast cancer</kwd>
<kwd>alternative medicine</kwd>
<kwd>immunomodulation</kwd>
<kwd>genotoxicity</kwd>
</kwd-group>
<funding-group>
<funding-statement>The author(s) declared that financial support was received for this work and/or its publication. Funding from Amrita Vishwa Vidyapeetham, India.</funding-statement>
</funding-group>
<counts>
<fig-count count="2"/>
<table-count count="3"/>
<equation-count count="0"/>
<ref-count count="49"/>
<page-count count="10"/>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Ethnopharmacology</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="s1">
<label>1</label>
<title>Introduction</title>
<p>According to the GLOBOCAN 2020 estimates, breast cancer has become the most frequently diagnosed cancer worldwide, with over 2.26 million new cases and nearly 685,000 deaths reported in 2020 (<xref ref-type="bibr" rid="B40">Sung et al., 2021</xref>). This makes it a leading global health challenge. In earlier days mastectomy followed by chemotherapy was the standard treatment for breast cancer. At the same time, they have limitations such as negative impact on quality of life, drug resistance and toxicity (<xref ref-type="bibr" rid="B49">Zafar et al., 2025</xref>). These challenges shifted researchers to integrative approaches and novel therapies like biocompatible nanomedicines. The traditional Ayurvedic medicine <italic>Abhraka bhasma</italic> which consists of mica nanoparticles has been identified as an alternative medicine and potential adjunct for cancer therapy.</p>
<p>
<italic>Bhasma</italic>s are Ayurvedic nano medicines prepared by processing metals and minerals with herbal products to eliminate their toxicity and confer therapeutic properties (<xref ref-type="bibr" rid="B21">Kantak et al., 2020</xref>; <xref ref-type="bibr" rid="B35">Sharma, 2004</xref>; <xref ref-type="bibr" rid="B1">Acharya, 2015</xref>; <xref ref-type="bibr" rid="B15">Government of India, 2003</xref>; <xref ref-type="bibr" rid="B48">Wele et al., 2021</xref>). As the particles in the final product are reportedly within the nanometer range, they are considered nanomedicines (<xref ref-type="bibr" rid="B21">Kantak et al., 2020</xref>). <italic>Abhraka Bhasma</italic> an incinerated herbo-metallic preparation of mica, is widely used by traditional medicine practitioners (<xref ref-type="bibr" rid="B7">Chatterjee et al., 2024</xref>) for managing <italic>Arbuda</italic> (tumors). This is based on its traditionally attributed properties, such as <italic>Rasayana</italic> (rejuvenating), detoxifying nature, and immune-supportive properties.</p>
<p>Breast cancer, the most frequently diagnosed cancer worldwide, is a leading global health challenge. In Ayurveda, Breast cancer (<italic>Stanarbuda</italic>) is attributed to a <italic>tridosha</italic> (vital forces) imbalance causing abnormal <italic>Mamsa Dhatu</italic> (muscle tissue proliferation). The rationale for using Abhraka Bhasma is that its properties counter this pathology. Its Madhura rasa (Sweet taste) and Sheeta virya (cold nature) make it a Rasayana (rejuvenator) to restore Ojas (immunity). It is Tridoshahara (balancing doshas), and its Lekhana (scraping) Karma is traditionally thought to clear the abnormal Mamsa Dhatu proliferation.</p>
</sec>
<sec id="s2">
<label>2</label>
<title>Abhraka Bhasma</title>
<sec id="s2-1">
<label>2.1</label>
<title>Mechanism of preparation and composition of <italic>Abhraka Bhasma</italic>
</title>
<p>
<italic>Abhraka Bhasma</italic> is a nanoparticle-based medicine derived from raw mica (<xref ref-type="bibr" rid="B21">Kantak et al., 2020</xref>). Its preparation involves traditional pharmaceutical processes, primarily <italic>shodhana</italic> (purification) followed by numerous cycles of <italic>puta</italic> (incineration) (4, p. 474&#x2013;476, 5, p. 67&#x2013;69, 5, p. 65&#x2013;72, 7). The <italic>puta</italic> (calcination) is the key nano-transformation step (4, p. 476&#x2013;495, 5, p. 68&#x2013;72, 7, 8, 9), designed to convert the raw material into a non-toxic, bioavailable, and therapeutically potent medicine (<xref ref-type="fig" rid="F1">Figure 1</xref>). Analytical techniques confirm the final composition consists of oxides of iron, silica, alumina, magnesium, and potassium, with a reduced nanoparticle size of 20&#x2013;100&#xa0;nm (<xref ref-type="bibr" rid="B21">Kantak et al., 2020</xref>; <xref ref-type="bibr" rid="B48">Wele et al., 2021</xref>) (<xref ref-type="table" rid="T1">Table 1</xref>).</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>A Schematic framework illustrating the preparation, characterization, and evidence levels for <italic>Abhraka Bhasma</italic> in cancer.</p>
</caption>
<graphic xlink:href="fphar-16-1656846-g001.tif">
<alt-text content-type="machine-generated">Flowchart illustrating evidence levels for Abhraka Bhasma. Starts with raw Abhraka&#x27;s purification and incineration leading to preclinical evidence. In vitro tests include cytotoxicity and apoptosis in MCF-7 cells; in vivo tests include geno-toxicity in albino rats. Level four shows case reports of Ayurvedic regimens in breast cancer. Levels one to three state no randomized controlled trials to date.</alt-text>
</graphic>
</fig>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>Comparitive Analysis of <italic>Abhraka Bhasma</italic> and Biomedical Mica (STB- HO), Quantitative Toxicology of <italic>Abhraka Bhasma</italic> and Safety profile.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Parameters</th>
<th align="left">
<italic>Abhraka Bhasma</italic> (mica nanoparticles)</th>
<th align="left">STB- HO (biomedical Mica)</th>
<th align="left">References</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">Preparation</td>
<td align="left">A series of pharmaceutical processes involving purification (shodhana), and incineration (marana)</td>
<td align="left">Mica is purified and physically processed by dry cutting or milling techniques to get small particle size</td>
<td align="left">
<xref ref-type="bibr" rid="B21">Kantak et al. (2020)</xref>, <xref ref-type="bibr" rid="B8">Cho et al. (2013)</xref>
</td>
</tr>
<tr>
<td align="left">Composition</td>
<td align="left">KMg<sub>3</sub>(Si<sub>3</sub>Al)O<sub>10</sub>(OH)<sub>2</sub>
</td>
<td align="left">Alumino silicate</td>
<td align="left">
<xref ref-type="bibr" rid="B21">Kantak et al. (2020)</xref>, <xref ref-type="bibr" rid="B48">Wele et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="left">Elemental composition</td>
<td align="left">Si(14.18%), Al (7.58%), Mg (5.03%), Fe (12.64%), K (8.36%), Na (1.39%), Rb, Ca (3.64%), O (35.69%), C (9.57%), Ti (1.16%), Cs, P (0.76%), Mn, Cr, Li, Ba</td>
<td align="left"/>
<td align="left">
<xref ref-type="bibr" rid="B21">Kantak et al. (2020)</xref>, <xref ref-type="bibr" rid="B48">Wele et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="left">Particle size distribution</td>
<td align="left">SEM - 92.3&#xa0;nm<break/>TEM &#x2013; 50&#xa0;nm to 1&#xa0;&#xb5;m<break/>XRD &#x2013; 62&#xa0;nm</td>
<td align="left">Nanometer range</td>
<td align="left">
<xref ref-type="bibr" rid="B21">Kantak et al. (2020)</xref>, <xref ref-type="bibr" rid="B48">Wele et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="left">Dosing</td>
<td align="left">120 mg&#x2013;360&#xa0;mg/kg body weight</td>
<td align="left">100&#xa0;mg/kg body weight (animal models)</td>
<td align="left">
<xref ref-type="bibr" rid="B23">Kulala et al. (2023)</xref>, <xref ref-type="bibr" rid="B8">Cho et al. (2013)</xref>
</td>
</tr>
<tr>
<td align="left">Toxicity outcomes with methods and acute/sub- acute metrics</td>
<td align="left">Low acute toxicity but at higher doses reported to have reversible, dose-dependent hepatotoxicity, No genotoxicity</td>
<td align="left">No adverse effects like loss of body weight or abnormal behaviour, reported in animal models suggesting low toxicity profile <italic>in vivo</italic>
</td>
<td align="left">
<xref ref-type="bibr" rid="B8">Cho et al. (2013)</xref>, <xref ref-type="bibr" rid="B14">Gopinath and Shivashankar (2021)</xref>, <xref ref-type="bibr" rid="B29">Pandit et al. (2024)</xref>
</td>
</tr>
<tr>
<td rowspan="4" align="left">Toxicity data of abhraka bhasma</td>
<td colspan="2" align="left">&#x2a;Acute toxicity - LD50 as per OECD guidelines in rat model shows no toxicity upto 2000&#xa0;mg/kg AB orally for 2 weeks&#x2a;Sub-acute toxicity of different AB doses showed no significant variation when compared with the control</td>
<td align="left">
<xref ref-type="bibr" rid="B14">Gopinath and Shivashankar (2021)</xref>
</td>
</tr>
<tr>
<td colspan="2" align="left">Low acute toxicity but at higher doses reported to have reversible, dose-dependent hepatotoxicity</td>
<td align="left">
<xref ref-type="bibr" rid="B29">Pandit et al. (2024)</xref>
</td>
</tr>
<tr>
<td colspan="2" align="left">&#x2a;Sub-acute toxicity &#x2013; NOAEL, as per OECD 407, for 28-days, in Sprague-Dawley rats upto 1280 mg/kg b.w.a formulation containing AB, shows no changes in the body weight, organ weight &#x0026; haematologicaical parameters</td>
<td align="left">
<xref ref-type="bibr" rid="B2">Balakrishna et al. (2025)</xref>
</td>
</tr>
<tr>
<td colspan="2" align="left">&#x2a; Genotoxicity, in swiss albino rats at a dose of 120&#xa0;mg/kg or 360&#xa0;mg/kg body weight - nongenotoxic, enhance DNA repair capacity</td>
<td align="left">
<xref ref-type="bibr" rid="B23">Kulala et al. (2023)</xref>
</td>
</tr>
<tr>
<td colspan="4" align="center" style="background-color:#FFFFFF">Safety data (<xref ref-type="bibr" rid="B16">International Council for Harmonisation ICH, 2022</xref>)</td>
</tr>
<tr>
<td colspan="4" align="left" style="background-color:#FFFFFF">Metal regulatory limit<break/>Mercury (Hg) - 30&#xa0;&#x3bc;g/day<break/>Arsenic (as) - 15&#xa0;&#x3bc;g/day<break/>Lead (Pb) - 5&#xa0;&#x3bc;g/day</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s2-2">
<label>2.2</label>
<title>Mechanism of action of <italic>Abhraka Bhasma</italic>
</title>
<p>Mechanism of Action of <italic>Abhraka Bhasma</italic> against breast cancer is twofold. One demonstrates direct, dose-dependent cytotoxicity, inhibiting the proliferation of MCF-7, human breast cancer cells. Simultaneously, it exhibits significant immunomodulatory and anti-inflammatory effects by reducing nitric oxide production in the tumor microenvironment. <italic>Abhraka Bhasma</italic> is believed to trigger apoptosis, effectively targeting cancer cells while also regulating the surrounding immune response.</p>
</sec>
<sec id="s2-3">
<label>2.3</label>
<title>Quantitative toxicology data from standardized <italic>Abhraka Bhasma</italic>
</title>
<p>For the clinical translation of a Bhasma, the primary concern is safety (<xref ref-type="bibr" rid="B24">Kulkarni et al., 2024</xref>), which is directly connected to proper pharmaceutical preparation, heavy-metal content, and batch-to-batch consistency.</p>
<sec id="s2-3-1">
<label>2.3.1</label>
<title>LD50 and NOAEL</title>
<p>Preclinical toxicity studies indicate <italic>Abhraka Bhasma</italic> has low acute toxicity, with an LD50 &#x3e; 2000&#xa0;mg/kg in rats, classifying it as non-toxic per OECD guidelines (<xref ref-type="bibr" rid="B14">Gopinath and Shivashankar, 2021</xref>). However, a 28-day sub-acute study suggested reversible, dose-dependent hepatotoxicity at higher doses, requiring careful dosage (<xref ref-type="bibr" rid="B29">Pandit et al., 2024</xref>). In contrast, another subacute study on a formulation containing it established a NOAEL &#x3e;1000&#xa0;mg/kg/day with no toxicologically relevant changes (<xref ref-type="bibr" rid="B2">Balkrishna et al., 2025</xref>). Furthermore, it was found to be non-genotoxic and to enhance DNA base excision repair capacity in mice (<xref ref-type="bibr" rid="B23">Kulala et al., 2023</xref>) (<xref ref-type="table" rid="T1">Table 1</xref>).</p>
</sec>
<sec id="s2-3-2">
<label>2.3.2</label>
<title>Elemental profile and heavy-metal risk</title>
<p>Quantitative analysis of standardized <italic>Abhraka Bhasma</italic> indicates a typical elemental profile. A study by Wele et al., reported the elemental constitution of <italic>Abhraka Bhasma</italic> as Si(14.18%),Al (7.58%),Mg (5.03%),Fe (12.64%),K (8.36%),Na (1.39%),Ca (3.64%),O (35.69%), C (9.57%),Ti (1.16%), P (0.76%),Mn, Cr, Li, Ba, Rb, Cs (<xref ref-type="bibr" rid="B21">Kantak et al., 2020</xref>; <xref ref-type="bibr" rid="B48">Wele et al., 2021</xref>). A study by Bhatia et al., (<xref ref-type="bibr" rid="B5">Bhatia and Kale, 2013</xref>), reported the absence of toxic heavy metals like Mercury and organic compounds in <italic>Abhraka Bhasma</italic>. But the high percentage of aluminum (Al) in the formulation is a notable finding that warrants further toxicological assessment (<xref ref-type="table" rid="T1">Table 1</xref>).</p>
</sec>
<sec id="s2-3-3">
<label>2.3.3</label>
<title>Bioaccessibility</title>
<p>Bioaccessibility is the amount of a nutrient or compound that is released during digestion and made available for absorption in the small intestine. It is a crucial step in the overall process of bioavailability. A study conducted by Kantak et al., revealed that the bio-accessibility of elements like K, Ca, Al, Fe, Na and Si in <italic>Abhraka Bhasma</italic> is greater in gastric digestion than in gastro-intestinal digestion (<xref ref-type="bibr" rid="B20">Kantak and Rajurkar, 2023</xref>).</p>
</sec>
<sec id="s2-3-4">
<label>2.3.4</label>
<title>Batch variability</title>
<p>Batch-to-batch variability, stemming from different source materials or processing, is a key challenge for standardizing <italic>Abhraka Bhasma</italic>. <xref ref-type="bibr" rid="B21">Kantak et al. (2020)</xref>, compared two traditional preparation methods and two commercial samples, finding that different methods yield physically different end-products (e.g., varying nanoparticle proportions), which they hypothesized could correlate with efficacy. This demonstrates that manufacturing differences make it difficult to generalize safety, toxicity, or efficacy data from a single preparation.</p>
</sec>
<sec id="s2-3-5">
<label>2.3.5</label>
<title>Pharmacovigilance considerations</title>
<p>Any future clinical application would necessitate not only stringent ethical approval but also robust pharmacovigilance systems to proactively monitor for potential adverse effects, particularly those related to its elemental composition. This post-marketing surveillance is an essential regulatory requirement for ensuring patient safety during any potential clinical integration.</p>
</sec>
</sec>
<sec id="s2-4">
<label>2.4</label>
<title>Distinguishing traditional <italic>Abhraka Bhasma</italic> from STB HO-modern biomedical mica</title>
<p>Abhraka Bhasma prepared by traditional Ayurvedic methods and STB HO, Biomedical Mica are both described as Mica nanoparticles, but they are prepared by distinctly different methods. The preparation of <italic>Abhraka Bhasma</italic> involves a series of pharmaceutical processes including purification (<italic>Shodhana</italic>), and incineration (<italic>Marana</italic>) which are intended to transform raw mica into a non-toxic, nanoparticle-based medicine (<xref ref-type="bibr" rid="B21">Kantak et al., 2020</xref>). <italic>Shodhana</italic> involves repeated heating and quenching of <italic>Abhraka</italic> in liquid media such as milk or herbal decotions. This is followed by <italic>marana</italic> which involves repeated incinerations after trituration with herbal juices. Studies on <italic>Abhraka Bhasma</italic> have reported its anti-tumor, immunomodulatory, anti-inflammatory, antioxidant, cell regeneration, DNA repair mechanisms and immunostimulatory actions (<xref ref-type="bibr" rid="B21">Kantak et al., 2020</xref>; <xref ref-type="bibr" rid="B35">Sharma, 2004</xref>; <xref ref-type="bibr" rid="B1">Acharya, 2015</xref>; <xref ref-type="bibr" rid="B48">Wele et al., 2021</xref>; <xref ref-type="bibr" rid="B28">Pandey et al., 2022</xref>; <xref ref-type="bibr" rid="B17">Jani et al., 2021</xref>) (<xref ref-type="table" rid="T1">Table 1</xref>).</p>
<p>In contrast, formulations like STB-HO are purified mineral preparations. They are typically manufactured using modern mechanical or physical methods (dry cutting techniques or milling) to achieve a fine particle or nanoparticle size. This process results in nanoparticles, but lacks the repeated incineration and incorporation of herbal-derived organic components seen in the <italic>bhasma</italic> preparation. STB-HO is a medical-grade aluminosilicate mineral derivative in biomedical research. It is a processed form of the natural mineral mica (an aluminosilicate mineral), converted into fine or nanoparticles. Studies on STB-HO, have demonstrated Immunostimulatory, chemopreventive and teratoma prevention action (<xref ref-type="bibr" rid="B19">Kang et al., 2015</xref>; <xref ref-type="bibr" rid="B8">Cho et al., 2013</xref>; <xref ref-type="bibr" rid="B9">Choi et al., 2016</xref>). A primary limitation is the scarcity of detailed, publicly available information regarding STB-HO&#x2019;s precise manufacturing, standardization, and physicochemical characterization, which hinders direct, rigorous comparisons with traditional <italic>Abhraka Bhasma</italic> and limits a full understanding of its distinct pharmacological profile.</p>
</sec>
</sec>
<sec id="s3">
<label>3</label>
<title>Anticancer potential: preclinical <italic>In vitro</italic> evidence (level 5)</title>
<p>
<italic>In vitro</italic> evidence for the anticancer potential of <italic>Abhraka Bhasma</italic> and STB HO (Biomedical Mica nanoparticles) is shown in (<xref ref-type="fig" rid="F2">Figure 2</xref>) (<xref ref-type="table" rid="T2">Table 2</xref>).</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Anticancer potential of <italic>Abhraka Bhasma</italic> (Mica nanoparticles).</p>
</caption>
<graphic xlink:href="fphar-16-1656846-g002.tif">
<alt-text content-type="machine-generated">Diagram illustrating the anticancer potential of Abhraka Bhasma. Central circle labeled &#x22;Anticancer Potential of Abhraka Bhasma&#x22; with arrows pointing to eight effects: cytotoxicity, teratoma inhibition, genotoxicity, chemopreventive action, immunostimulation, oxidative stress modulation, immunomodulation, and proliferation and apoptosis. Each effect is associated with specific assays or biological models, including MCF-7 breast cancer cells, undifferentiated hES cells, Swiss Albino rats, athymic nude mice, Drosophila melanogaster, and RAW 264.7 cells.</alt-text>
</graphic>
</fig>
<table-wrap id="T2" position="float">
<label>TABLE 2</label>
<caption>
<p>Per-study extraction.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="center">Material</th>
<th align="center">Model</th>
<th align="center">Dose</th>
<th align="center">Exposure</th>
<th align="center">Controls</th>
<th align="center">Statistics</th>
<th align="center">Main outcomes</th>
<th align="center">Limitations</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="center">Abhraka bhasma (<xref ref-type="bibr" rid="B37">Sreelakshmi and Nandagopalan, 2024</xref>)</td>
<td align="center">MCF-7 breast cancer cells</td>
<td align="center">10, 50, 100, 200&#xa0;&#x3bc;g/mL</td>
<td align="center">48&#xa0;h</td>
<td align="center">0.1% DMSO</td>
<td align="left"/>
<td align="center">Dose-dependent cytotoxicity (49.22% cell death at 200&#xa0;&#x3bc;g/mL) and apoptotic morphology</td>
<td align="center">Lack of selective toxicity</td>
</tr>
<tr>
<td align="center">Abhraka bhasma (<xref ref-type="bibr" rid="B37">Sreelakshmi and Nandagopalan, 2024</xref>)</td>
<td align="center">RAW 264.7 cells (LPS-stimulated)</td>
<td align="center">50, 100, 200&#xa0;&#x3bc;g/mL</td>
<td align="center">A defined incubation period</td>
<td align="center">LPS (1&#xa0;&#x3bc;g/mL) treated cells</td>
<td align="left">Significant reduction</td>
<td align="center">Dose-dependent decrease in nitrite levels, suggesting immunomodulatory effects</td>
<td align="center">True effect unclear-whether effect or toxicity?</td>
</tr>
<tr>
<td align="center">Shataputi abhraka bhasma (<xref ref-type="bibr" rid="B43">Tamhankar and Gharote, 2020</xref>)</td>
<td align="center">Lung (HOP-62), leukemia (U-937), prostate (DU-145) cells</td>
<td align="center">10, 20, 40, 80&#xa0;&#x3bc;g/mL</td>
<td align="left"/>
<td align="center">Adriamycin (positive control)</td>
<td align="center">Statistically highly significant</td>
<td align="center">Anticancer activity on all three cell lines, especially prostate (DU-145)</td>
<td align="left"/>
</tr>
<tr>
<td align="center">Mica nanoparticle STB-HO (<xref ref-type="bibr" rid="B19">Kang et al., 2015</xref>)</td>
<td align="center">MCF-7 cells; co-culture with macrophages, DCs, and NK cells</td>
<td align="center">10&#xa0;&#x3bc;g/mL and 50&#xa0;&#x3bc;g/mL</td>
<td align="center">72&#xa0;h (proliferation); 48&#xa0;h (macrophages); 4&#xa0;h (NK co-culture)</td>
<td align="center">Untreated cells; Unstimulated controls</td>
<td align="center">p &#x3c; 0.001 (macrophages); p &#x3c; 0.01 (NK cells)</td>
<td align="center">No direct cytotoxicity, but significant immunomodulation (M1 macrophage skewing, NK cell activation)</td>
<td align="center">No statistically significant direct effect</td>
</tr>
<tr>
<td align="center">STB-HO mica fine particle (<xref ref-type="bibr" rid="B9">Choi SW et al., 2016</xref>)</td>
<td align="center">hES cells; <italic>in vivo</italic> teratoma xenotransplantation</td>
<td align="center">
<italic>In vitro</italic>: 1, 10, 100&#xa0;&#x3bc;g/mL; in vivo: 10&#xa0;&#x3bc;g/mL pre-treatment</td>
<td align="center">
<italic>In vitro</italic>: 24&#xa0;h (pre-treatment)</td>
<td align="center">Untreated cultures; vehicle treated group</td>
<td align="center">p &#x3c; 0.05 (<italic>in vitro</italic>); &#x201c;statistically significant&#x201d; (<italic>in vivo</italic>)</td>
<td align="center">Selectively eliminated undifferentiated hES cells; pre-treatment prevented teratoma formation (0/15 vs. 10/10)</td>
<td align="center">Specific to undifferentiated hES cells</td>
</tr>
<tr>
<td align="center">Abhraka bhasma (<xref ref-type="bibr" rid="B23">Kulala et al., 2023</xref>)</td>
<td align="center">Swiss albino mice</td>
<td align="center">120&#xa0;mg/kg or 360&#xa0;mg/kg</td>
<td align="center">Orally, daily for 7&#xa0;days</td>
<td align="left"/>
<td align="center">p &#x3e; 0.05 (no toxicity); p &#x3c; 0.05 (protection)</td>
<td align="center">Not genotoxic; protected against EMS-induced chromosomal damage</td>
<td align="center">Dose-dependent toxicity at high concentrations</td>
</tr>
<tr>
<td align="center">Particled mica (STB-HO) (<xref ref-type="bibr" rid="B8">Cho et al., 2013</xref>)</td>
<td align="center">BALB/c athymic nude mice (HCT116 xenograft)</td>
<td align="center">50&#xa0;mg/kg or 100&#xa0;mg/kg</td>
<td align="center">Orally for 41&#xa0;days</td>
<td align="center">Untreated control</td>
<td align="center">p &#x3c; 0.05</td>
<td align="center">Significantly suppressed final tumor weight at 100&#xa0;mg/kg</td>
<td align="center">No direct cytotoxicity</td>
</tr>
<tr>
<td align="center">Mica nanoparticle (STB-HO) (<xref ref-type="bibr" rid="B19">Kang et al., 2015</xref>)</td>
<td align="center">MCF-7 xenograft model (athymic mice)</td>
<td align="center">35&#xa0;mg/kg or 70&#xa0;mg/kg</td>
<td align="center">Orally, daily for 12&#xa0;weeks</td>
<td align="center">Saline-treated control</td>
<td align="center">p &#x3c; 0.05; p &#x3c; 0.01</td>
<td align="center">Significantly reduced final tumor volume and mass; increased splenic NK cells</td>
<td align="center">No direct cytotoxicity</td>
</tr>
<tr>
<td align="center">Abhraka bhasma (<xref ref-type="bibr" rid="B38">Subedi et al., 2018a</xref>)</td>
<td align="center">
<italic>Drosophila melanogaster</italic>
</td>
<td align="center">Diet supplemented</td>
<td align="center">Larval and adult stages</td>
<td align="left"/>
<td align="center">Significantly lowered</td>
<td align="center">Modulated SOD/catalase; decreased GSH (&#x223c;40&#x2013;70% in larvae, 31%&#x2013;36% in adults); increased CncC and Hsp70 gene expression</td>
<td align="center">Translational gap between the <italic>Drosophila</italic> model and human physiology</td>
</tr>
</tbody>
</table>
</table-wrap>
<sec id="s3-1">
<label>3.1</label>
<title>
<italic>Abhraka Bhasma</italic> (mica nanoparticles)</title>
<sec id="s3-1-1">
<label>3.1.1</label>
<title>Cytotoxicity on MCF-7 breast cancer cells</title>
<p>
<xref ref-type="bibr" rid="B37">Sreelakshmi and Nandagopalan (2024)</xref> reported a dose-dependent cytotoxicity (<xref ref-type="bibr" rid="B47">Van Meerloo et al., 2011</xref>) of <italic>Abhraka Bhasma</italic> in MCF-7 cells (<xref ref-type="bibr" rid="B25">Lee et al., 2015</xref>). It has a high IC50 value of 193.2&#xa0;&#x3bc;g/mL indicating weak potency (<xref ref-type="bibr" rid="B37">Sreelakshmi and Nandagopalan, 2024</xref>). The authors cited morphological observations such as cell shrinkage as evidence of an apoptotic anticancer effect. But these findings are not definitive. Such morphological changes are only suggestive and lack the necessary molecular validation to confirm the pathway. The most significant drawback of this study is the lack of selective toxicity. The study also assessed toxicity against a healthy macrophage cell line (RAW 264.7) and found that the 200&#xa0;&#x3bc;g/mL dose killed 46.15% of these healthy cells (<xref ref-type="bibr" rid="B37">Sreelakshmi and Nandagopalan, 2024</xref>). This demonstrates a complete absence of a therapeutic window, as the cytotoxicity against the healthy cell line (46.15%) is nearly identical to that against the cancer cell line (49.22%) at the same concentration.</p>
</sec>
<sec id="s3-1-2">
<label>3.1.2</label>
<title>Immunomodulatory activity on RAW 264.7 cells</title>
<p>
<xref ref-type="bibr" rid="B37">Sreelakshmi and Nandagopalan (2024)</xref> evaluated <italic>Abhraka Bhasma</italic> in different concentrations (50, 100, 200&#xa0;&#x3bc;g/mL) on LPS-stimulated RAW 264.7 cells (<xref ref-type="bibr" rid="B42">Taciak et al., 2018</xref>), measuring nitrite, a key inflammatory molecule (<xref ref-type="bibr" rid="B37">Sreelakshmi and Nandagopalan, 2024</xref>). The study reported a dose-dependent decrease in nitrite levels (<xref ref-type="bibr" rid="B37">Sreelakshmi and Nandagopalan, 2024</xref>; <xref ref-type="bibr" rid="B26">Lepoivre et al., 1990</xref>; <xref ref-type="bibr" rid="B13">Gavrilas et al., 2019</xref>), which suggest a specific anti-inflammatory effect of the drug, possibly by inhibiting iNOS (<xref ref-type="bibr" rid="B10">Coleman, 2001</xref>). The same study demonstrated 46.15% cell death in this cell line at the 200&#xa0;&#x3bc;g/mL concentration (<xref ref-type="bibr" rid="B37">Sreelakshmi and Nandagopalan, 2024</xref>). This high toxicity makes it impossible to analyse specific pathway inhibition from a simple reduction in viable, nitrite-producing cells. The observed anti-inflammatory effect is the expected outcome when nearly half the cell population is non-viable. Though these findings suggests that <italic>Abhraka Bhasma</italic> has an immunomodulatory effect on RAW 264.7 cells, it is unclear if this finding represents a true immunomodulatory effect or is simply a consequence of <italic>Abhraka Bhasma</italic> being toxic to the macrophage cells at the tested concentrations (<xref ref-type="bibr" rid="B37">Sreelakshmi and Nandagopalan, 2024</xref>).</p>
</sec>
<sec id="s3-1-3">
<label>3.1.3</label>
<title>Anticancer activity of <italic>Shataputi Abhraka Bhasma</italic> (100 times incinerated mica)</title>
<p>In a study conducted by Tamhankar YL et al. on <italic>Shataputi Abhraka Bhasma</italic> containing mica nanoparticles, incinerated 100 times, various concentrations (10&#xa0;&#x3bc;g/mL, 20&#xa0;&#x3bc;g/mL, 40&#xa0;&#x3bc;g/mL, 80&#xa0;&#x3bc;g/ML) of <italic>Shataputi Abhraka Bhasma</italic> were introduced into three cancer cell lines and compared against positive control drug Adriamycin. (<xref ref-type="bibr" rid="B43">Tamhankar and Gharote, 2020</xref>; <xref ref-type="bibr" rid="B35">Sharma, 2004</xref>). This <italic>in vitro</italic> study demonstrated dose-dependent cytotoxicity, with the highest potency observed against the prostate (DU-145) cell line (GI50 &#x3d; 31.2&#xa0;&#x3bc;g/mL) compared to lung (HOP-62) and leukemia (U-937) cells (<xref ref-type="bibr" rid="B43">Tamhankar and Gharote, 2020</xref>). (<xref ref-type="bibr" rid="B43">Tamhankar and Gharote, 2020</xref>). While this paper was limited to a cytotoxicity screen and did not investigate the causal mechanism, it is hypothesized that the anticancer activity is likely attributable to the mica nanoparticles penetrating the cancer cells, where they induce high levels of Reactive Oxygen Species (ROS), leading to overwhelming oxidative stress and the activation of the apoptotic cell death pathway.</p>
</sec>
</sec>
<sec id="s3-2">
<label>3.2</label>
<title>STB -HO (Biomedical Mica)</title>
<sec id="s3-2-1">
<label>3.2.1</label>
<title>Proliferation and apoptosis in MCF-7 breast cancer cells</title>
<p>An <italic>in vitro</italic> study tested Mica Nanoparticle STB-HO (10 and 50&#xa0;&#x3bc;g/mL) on MCF-7 cells for 72&#xa0;h, using untreated cells as a control (<xref ref-type="bibr" rid="B19">Kang et al., 2015</xref>). While STB-HO had no statistically significant direct effect on MCF-7 proliferation or apoptosis. (<xref ref-type="bibr" rid="B12">Ebihara et al., 2023</xref>). However, STB-HO demonstrated potent indirect anti-tumor activity by activating immune cells. It significantly polarized macrophages toward an immunostimulatory M1 phenotype (P &#x3c; 0.001) after 48&#xa0;h (<xref ref-type="bibr" rid="B19">Kang et al., 2015</xref>). Furthermore, in a 4-h co-culture with NK cells, STB-HO at (10&#xa0;&#x3bc;g/mL and 50&#xa0;&#x3bc;g/mL) generated IFN-&#x3b3;&#x2013;secreting effector cells (<xref ref-type="bibr" rid="B44">Tau and Rothman, 2001</xref>), causing a statistically significant (P &#x3c; 0.01) increase in immune cells that can kill MCF-7 cells (<xref ref-type="bibr" rid="B44">Tau and Rothman, 2001</xref>). STB-HO functions as an immunomodulator rather than a direct cytotoxic agent, suppressing MCF-7 cells indirectly by polarizing macrophages toward an anti-tumor M1 phenotype and stimulating IFN-&#x3b3;&#x2013;secreting NK cells.</p>
</sec>
<sec id="s3-2-2">
<label>3.2.2</label>
<title>Inhibition of teratoma-forming ability in hES cells</title>
<p>In a study conducted by Choi SW et al., the anti-tumorigenic activity of STB-HO Mica fine particle in hES cells (Human Embryonic Stem Cell) (<xref ref-type="bibr" rid="B30">Park et al., 2024</xref>) was investigated by administering different concentrations (1, 10, and 100&#xa0;&#x3bc;g/mL) of Mica fine particles into hES cell (Human Embryonic Stem Cell) (<xref ref-type="bibr" rid="B30">Park et al., 2024</xref>) and compared against untreated control cultures (<xref ref-type="bibr" rid="B9">Choi et al., 2016</xref>). The study found that STB-HO treatment in differentiating cultures selectively induced apoptosis only in the remaining undifferentiated hESCs, without harming the differentiated cells. This mechanism was p53-dependent. At 10&#xa0;&#x3bc;g/mL, it activated p53, p21, and pro-apoptotic proteins (Bim, Puma, p-Bad) (<xref ref-type="bibr" rid="B18">Jourdan et al., 2009</xref>) while suppressing the anti-apoptotic gene BIRC5 (<xref ref-type="bibr" rid="B13">Gavrilas et al., 2019</xref>). This selective elimination of pluripotent cells was validated <italic>in vivo.</italic> hES cells pre-treated with 10&#xa0;&#x3bc;g/mL STB-HO were incapable of forming teratomas upon xenotransplantation (0/15 animals), a statistically significant contrast to the 100% teratoma formation (10/10 animals) in controls. These findings suggest that pre-treatment of differentiating hES cell cultures with STB-HO can prevent teratoma formation after stem cell transplantation (<xref ref-type="bibr" rid="B9">Choi et al., 2016</xref>). However, the mechanism of p53-dependent apoptosis was highly specific to undifferentiated hES cells during the differentiation process.</p>
</sec>
</sec>
</sec>
<sec id="s4">
<label>4</label>
<title>Anticancer potential: preclinical <italic>In vivo</italic> evidence (level 5)</title>
<p>
<italic>In vivo</italic> evidence for the anticancer potential of <italic>Abhraka Bhasma</italic> and STB HO (Biomedical Mica nanoparticles) is shown in (<xref ref-type="fig" rid="F2">Figure 2</xref>; <xref ref-type="table" rid="T2">Table 2</xref>).</p>
<sec id="s4-1">
<label>4.1</label>
<title>Genotoxicity and DNA repair potential in swiss albino rats</title>
<p>Following OECD guidelines, an acute oral toxicity study was conducted by Kulala et al., in a Swiss albino mouse model (n &#x3d; 3) (<xref ref-type="bibr" rid="B23">Kulala et al., 2023</xref>). The dosing regimen consisted of 120&#xa0;mg/kg or 360&#xa0;mg/kg body weight of <italic>Abhraka Bhasma</italic> administered orally daily for 7&#xa0;days. The study (n &#x3d; 6) confirmed <italic>Abhraka Bhasma</italic> was neither genotoxic (micronucleus assay) nor reproductively toxic (sperm abnormality assay) (<xref ref-type="bibr" rid="B23">Kulala et al., 2023</xref>). Significantly, it demonstrated a potent chemoprotective role, reducing (p &#x3c; 0.05) chromosomal damage induced by the mutagen ethyl methanesulfonate. This protection was mechanistically linked to an enhanced constitutive DNA base excision repair (BER) capacity, as validated by an <italic>in vitro</italic> comet-based repair assay (<xref ref-type="bibr" rid="B23">Kulala et al., 2023</xref>). This suggests the formulation bolsters intrinsic DNA repair pathways. Even though the study results suggested it to be nongenotoxic, it also provides evidence of dose-dependent toxicity at high concentrations, which was reflected as mild histopathological (liver and kidney) changes observed at the 360&#xa0;mg/kg dose.</p>
</sec>
<sec id="s4-2">
<label>4.2</label>
<title>Chemopreventive action on athymic nude mice</title>
<p>
<xref ref-type="bibr" rid="B32">Rajput et al. (2008)</xref>, <xref ref-type="bibr" rid="B8">Cho et al. (2013)</xref> examined Mica (STB-HO) in a colorectal cancer Xenograft model (n &#x3d; 6) (HCT116 cells). Oral administration of 100&#xa0;mg/kg significantly suppressed final tumor weight (p &#x3c; 0.05). Subsequent <italic>in vitro</italic> mechanistic studies elucidated the pathway. Mechanistic studies like immunoblotting, cytotoxicity assay, FACs analysis and measurement of matrix metalloproteinase 9 (MMP-9) secretion were also performed on HCT116 and human umbilical vein endothelial cells (HUVECs) for 24&#xa0;h (<xref ref-type="bibr" rid="B11">Duranova et al., 2024</xref>). However, a critical finding from the study is that this anti-tumor effect was not due to direct cytotoxicity of the drug, but was attributed to Cytostatic Effects: Inducing G1 arrest and Anti-angiogenic Effects: inhibiting VEGFR2. The G1 arrest was mediated by the upregulation of p21 and p27, while the anti-angiogenic effect was linked to the suppression of VEGF-induced VEGFR2 phosphorylation (<xref ref-type="bibr" rid="B31">Prasetiyo and Wahjoepramono, 2024</xref>), effectively halting both proliferation and the tumor&#x2019;s blood supply.</p>
</sec>
<sec id="s4-3">
<label>4.3</label>
<title>Immunostimulatory effects on MCF-7 xenograft model</title>
<p>A study by <xref ref-type="bibr" rid="B19">Kang et al. (2015)</xref> in an MCF-7 xenograft model (n &#x3d; 5, NOG mice co-injected with human PBMCs) found oral STB-HO (35 and 70&#xa0;mg/kg) significantly reduced final tumor volume and mass (p &#x3c; 0.01) over 12&#xa0;weeks (<xref ref-type="bibr" rid="B19">Kang et al., 2015</xref>). A critical clarification from the study is that this anti-tumor effect was not due to direct cytotoxicity. This <italic>in vivo</italic> outcome was validated by <italic>in vitro</italic> co-culture assays, where STB-HO drove the activation and expansion of IFN-&#x3b3;&#x2013;secreting effector cells. Therefore, the anti-tumor effect of STB-HO is attributed to an indirect immunostimulatory mechanism, which suppresses tumor growth by enhancing the host&#x2019;s innate immune response, specifically via a significant expansion of the human natural killer (NK) cell population, observed both systemically and locally (tumor infiltration) (<xref ref-type="bibr" rid="B19">Kang et al., 2015</xref>).</p>
</sec>
<sec id="s4-4">
<label>4.4</label>
<title>Modulation of oxidative stress in <italic>Drosophila melanogaster</italic> model</title>
<p>Studies by Subedi et al. in <italic>Drosophila melanogaster</italic> demonstrated that Abhraka Bhasma supplementation induces a mild pro-oxidant signal, evidenced by a significant depletion of total GSH content (31%&#x2013;70%) (<xref ref-type="bibr" rid="B38">Subedi et al., 2018a</xref>). This appears to trigger a classic hormetic response, as this stress subsequently upregulated the adaptive antioxidant enzymes SOD and catalase (<xref ref-type="bibr" rid="B38">Subedi et al., 2018a</xref>). This mechanism was supported by another study from the group, which showed that <italic>Abhraka Bhasma</italic> increased the expression of the master stress-response genes CncC (the <italic>Drosophila</italic> Nrf2-equivalent) and Hsp70 (<xref ref-type="bibr" rid="B39">Subedi et al., 2018b</xref>). This suggests <italic>Abhraka Bhasma</italic> may enhance stress resilience by pre-conditioning these defensive pathways. However, the primary drawback of this entire line of evidence is the vast translational gap between the <italic>Drosophila</italic> model and human physiology.</p>
</sec>
</sec>
<sec id="s5">
<label>5</label>
<title>Ayurvedic rationale for use of <italic>Abhraka Bhasma</italic> in cancer/breast cancer</title>
<p>In <italic>Ayurveda</italic>, cancer-like conditions are termed <italic>Arbuda</italic> (malignant) and <italic>Granthi</italic> (benign) (<xref ref-type="bibr" rid="B38">Subedi et al., 2018a</xref>; <xref ref-type="bibr" rid="B39">Subedi et al., 2018b</xref>; <xref ref-type="bibr" rid="B41">Sushruta, 2008</xref>). <italic>Stanarbuda</italic> (Breast Cancer) (<xref ref-type="bibr" rid="B41">Sushruta, 2008</xref>; <xref ref-type="bibr" rid="B6">Charaka, 2009</xref>) is described as a hard mass (<xref ref-type="bibr" rid="B39">Subedi et al., 2018b</xref>; <xref ref-type="bibr" rid="B6">Charaka, 2009</xref>) resulting from a <italic>tridosha</italic> imbalance (<xref ref-type="bibr" rid="B34">Sen, 2005</xref>; <xref ref-type="bibr" rid="B41">Sushruta, 2008</xref>; <xref ref-type="bibr" rid="B6">Charaka, 2009</xref>) causing abnormal muscle (<italic>Mamsa Dhatu</italic>) proliferation and impaired metabolism (<italic>Agni</italic>). Its management (<xref ref-type="bibr" rid="B34">Sen, 2005</xref>; <xref ref-type="bibr" rid="B6">Charaka, 2009</xref>; <xref ref-type="bibr" rid="B41">Sushruta, 2008</xref>; <xref ref-type="bibr" rid="B46">Vagbhata, 2012</xref>) aims to remove toxins and balancing <italic>tridosha</italic> (<xref ref-type="bibr" rid="B6">Charaka, 2009</xref>; <xref ref-type="bibr" rid="B41">Sushruta, 2008</xref>).</p>
<sec id="s5-1">
<label>5.1</label>
<title>
<italic>Rasayana</italic> (rejuvenation) and <italic>Dhatu-Pushtikara</italic> (tissue nourishment) action of <italic>Abhraka Bhasma</italic> in <italic>arbuda</italic> (malignant tumor)</title>
<p>
<italic>Abhraka Bhasma</italic> is a potent <italic>Rasayana</italic> (rejuvenation) (41, 36, p. 109&#x2013;115, 215&#x2013;218; 34, p. 5&#x2013;36), traditionally used to enhance <italic>Ojas</italic> (immunity). <italic>Ojas</italic> correlates with modern immunomodulation and oxidative stress management (35, 37, 2008. p. 68&#x2013;71; 45, 46). It also enhances resilience and nourishes bone marrow (<italic>majja dhatu</italic>) (33, p. 474&#x2013;488; 42), providing a basis for counteracting systemic debility in cancer (<xref ref-type="table" rid="T3">Table 3</xref>).</p>
<table-wrap id="T3" position="float">
<label>TABLE 3</label>
<caption>
<p>Term mapping box of the Ayurvedic Rationale for <italic>Abhraka Bhasma</italic> in Cancer (<italic>Arbuda</italic>).</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Ayurvedic concept</th>
<th align="left">Literal meaning</th>
<th align="left">Modern correlation</th>
<th align="left">References</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left">
<italic>Arbuda/Stanarbuda</italic>
</td>
<td align="left">Malignant tumor/Breast cancer</td>
<td align="left">Cancer/Breast cancer</td>
<td align="left">
<xref ref-type="bibr" rid="B23">Kulala et al., 2023</xref>, <xref ref-type="bibr" rid="B6">Charaka, 2009</xref>
</td>
</tr>
<tr>
<td align="left">
<italic>Rasayana</italic>
</td>
<td align="left">Rejuvenation therapy</td>
<td align="left">Immunological resilience</td>
<td align="left">
<xref ref-type="bibr" rid="B34">Sen (2005)</xref>, <xref ref-type="bibr" rid="B41">Sushruta, 2008</xref>, <xref ref-type="bibr" rid="B46">Vagbhata, (2012)</xref>, <xref ref-type="bibr" rid="B36">Sharma et al. (2019)</xref>, <xref ref-type="bibr" rid="B22">Kuchewar et al. (2014)</xref>
</td>
</tr>
<tr>
<td align="left">
<italic>Tridosha Shamaka</italic>
</td>
<td align="left">
<italic>Dosha</italic>-pacifier (for <italic>Vata, Pitta, Kapha</italic>)</td>
<td align="left">Systemic Homeostasis, anti-inflammatory, immune modulation</td>
<td align="left">
<xref ref-type="bibr" rid="B34">Sen, 2005</xref>, <xref ref-type="bibr" rid="B41">Sushruta, 2008</xref>, <xref ref-type="bibr" rid="B46">Vagbhata, 2012</xref>
</td>
</tr>
<tr>
<td align="left">
<italic>Agni</italic>
</td>
<td align="left">Metabolic fire</td>
<td align="left">Metabolic Regulation, management of oxidative stress</td>
<td align="left">
<xref ref-type="bibr" rid="B6">Charaka, 2009</xref>, <xref ref-type="bibr" rid="B41">Sushruta, 2008</xref>, <xref ref-type="bibr" rid="B46">Vagbhata, 2012</xref>, <xref ref-type="bibr" rid="B33">Sawant and Mishra (2022)</xref>
</td>
</tr>
<tr>
<td align="left">
<italic>Lekhana</italic>
</td>
<td align="left">Scraping/Desiccation</td>
<td align="left">Anti-proliferative activity, Cytoreduction</td>
<td align="left">
<xref ref-type="bibr" rid="B33">Sawant and Mishra (2022)</xref>
</td>
</tr>
<tr>
<td align="left">
<italic>Dhatu-Pushtikara</italic>
</td>
<td align="left">Tissue nourishment</td>
<td align="left">Cellular/Tissue repair</td>
<td align="left">
<xref ref-type="bibr" rid="B41">Sushruta, 2008</xref>, <xref ref-type="bibr" rid="B46">Vagbhata, 2012</xref>
</td>
</tr>
<tr>
<td align="left">
<italic>Shothahara</italic>
</td>
<td align="left">Anti-inflammatory</td>
<td align="left">Anti-inflammatory activity</td>
<td align="left">
<xref ref-type="bibr" rid="B1">Acharya, 2015</xref>, <xref ref-type="bibr" rid="B46">Vagbhata, 2012</xref>, <xref ref-type="bibr" rid="B4">Bengal et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="left">
<italic>Krimighna</italic>
</td>
<td align="left">Anti-pathogenic</td>
<td align="left">Anti-microbial</td>
<td align="left">
<xref ref-type="bibr" rid="B1">Acharya, 2015</xref>, <xref ref-type="bibr" rid="B46">Vagbhata, 2012</xref>, <xref ref-type="bibr" rid="B4">Bengal et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="left">
<italic>Ojovardhak</italic>
<break/>
<italic>Vyadhikshamatva</italic>
</td>
<td align="left">Immune enhancer</td>
<td align="left">Immune modulation</td>
<td align="left">
<xref ref-type="bibr" rid="B34">Sen (2005)</xref>
</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s5-2">
<label>5.2</label>
<title>
<italic>Tridosha shamaka</italic> (dosha-pacifying properties)</title>
<p>
<italic>Abhraka Bhasma</italic> pacifies <italic>doshas</italic> (37, p. 68&#x2013;71, (<xref ref-type="bibr" rid="B46">Vagbhata, 2012</xref>), p. 94&#x2013;98), the traditional etiological factors for <italic>Arbuda</italic> (cancerous growth). This property correlates physiologically with its capacity for systemic immune modulation. Furthermore, it has the ability to restore <italic>agni</italic> (metabolic fire) and perform <italic>lekhana</italic> (scraping) (<xref ref-type="bibr" rid="B33">Sawant and Mishra, 2022</xref>). These properties provide a traditional basis for its role in managing oxidative stress and exhibiting anti-proliferative activity against pathological accumulations.</p>
</sec>
<sec id="s5-3">
<label>5.3</label>
<title>
<italic>Shothahara</italic> &#x26; <italic>krimighna</italic> (anti-inflammatory and anti-pathogenic)</title>
<p>
<italic>Abhraka Bhasma</italic> (Mica Nanoparticles) has anti-inflammatory activity (1). It also has Antimicrobial and anti-parasitic activity (<italic>Krimighna</italic>) which helps eliminate the microbial, cellular, and malignant or foreign entities (38, p. 94&#x2013;98, 44, 5, p. 67&#x2013;69) (<xref ref-type="table" rid="T3">Table 3</xref>).</p>
</sec>
<sec id="s5-4">
<label>5.4</label>
<title>
<italic>Ojovardhaka</italic> and <italic>Vyadhikshamatva</italic> (immune enhancer)</title>
<p>Arbuda (cancer) is a condition characterized by weakened immunity (Ojas). The Ayurvedic concept of <italic>Ojas</italic> can be understood as the collective immunological resilience of the body, which represents the optimal function of its neuro-immuno-endocrine axis. Ojas depletion in <italic>Arbuda</italic> (cancer) can be correlated with cancer-induced immunosuppression and high systemic inflammation. Abhraka Bhasma, which is <italic>Ojovardhaka</italic> (Ojas-enhancer), restores this vital essence and strengthens the body&#x2019;s innate cellular defense mechanisms against malignant transformation ((<xref ref-type="bibr" rid="B34">Sen, 2005</xref>), p. 841&#x2013;850, (<xref ref-type="bibr" rid="B46">Vagbhata, 2012</xref>), p. 923&#x2013;933).</p>
</sec>
</sec>
<sec id="s6">
<label>6</label>
<title>Clinical evidence on anticancer potential of <italic>Abhraka Bhasma</italic> (level 4)</title>
<p>On the evidence-based medicine hierarchy, the available clinical evidence for <italic>Abhraka Bhasma</italic> is limited to Level 4 (Case Reports) which is only hypothesis-generating and cannot be used to establish efficacy.</p>
<p>
<statement content-type="case" id="Case_1">
<label>Case 1</label>
<p>
<xref ref-type="bibr" rid="B27">Nimbalkar et al. (2024)</xref> reported a Stage III, Grade III invasive ductal carcinoma case managed with an integrative Ayurvedic regimen including <italic>Abhraka Bhasma</italic> (125&#xa0;mg/day) and <italic>Rasayana</italic> formulations post-chemotherapy (<xref ref-type="bibr" rid="B27">Nimbalkar et al., 2024</xref>). The patient had reduced toxicities and an 11-year disease-free interval, suggesting a role in long-term control (<xref ref-type="bibr" rid="B27">Nimbalkar et al., 2024</xref>).</p>
</statement>
</p>
<p>
<statement content-type="case" id="Case_2">
<label>Case 2</label>
<p>Similarly, <xref ref-type="bibr" rid="B3">Bendale et al. (2022)</xref> reported complete tumour regression in a patient managed exclusively with Ayurvedic medicines that included <italic>Abhraka Bhasma</italic> (<xref ref-type="bibr" rid="B3">Bendale et al., 2022</xref>). This case highlighted the <italic>Rasayana</italic> and immunomodulatory attributes of the formulation, suggesting its capacity to enhance host resilience and contribute to tumour regression.</p>
<p>While these uncontrolled observational reports describe better quality of life, and prolonged progression-free intervals in selected patients, these do not establish clinical efficacy.</p>
</statement>
</p>
</sec>
<sec sec-type="discussion" id="s7">
<label>7</label>
<title>Discussion</title>
<p>
<italic>Abhraka Bhasma</italic> (mica nanoparticles) exhibits dual pharmacological mechanisms. One pathway involves oxidative stress modulation (lowering GSH) (<xref ref-type="bibr" rid="B38">Subedi et al., 2018a</xref>) and the other, direct cytotoxicity, evidenced by dose-dependent effects on MCF-7 cells (<xref ref-type="bibr" rid="B37">Sreelakshmi and Nandagopalan, 2024</xref>), and genoprotection via enhanced DNA base excision repair (<xref ref-type="bibr" rid="B23">Kulala et al., 2023</xref>). A complementary mechanism, seen in STB-HO, operates via indirect, immune-mediated pathways. STB-HO showed no direct MCF-7 toxicity but enhanced tumor sensitivity to immune effectors, polarized macrophages to an M1 phenotype, and activated NK cells (<xref ref-type="bibr" rid="B19">Kang et al., 2015</xref>; <xref ref-type="bibr" rid="B12">Ebihara et al., 2023</xref>; <xref ref-type="bibr" rid="B44">Tau and Rothman, 2001</xref>). Its tumor suppression is linked to anti-angiogenic (VEGFR2 inhibition) and cytostatic (G1 cell cycle arrest) actions (<xref ref-type="bibr" rid="B32">Rajput et al., 2008</xref>; <xref ref-type="bibr" rid="B8">Cho et al., 2013</xref>; <xref ref-type="bibr" rid="B46">Vagbhata, 2012</xref>). This dual pharmacology parallels the Ayurvedic concepts of <italic>Rasayana</italic> (rejuvenation/immunity) (<xref ref-type="bibr" rid="B45">Tripathi, 2005</xref>; <xref ref-type="bibr" rid="B34">Sen, 2005</xref>; <xref ref-type="bibr" rid="B46">Vagbhata, 2012</xref>) and <italic>Lekhan</italic>a (anti-proliferation) (<xref ref-type="bibr" rid="B33">Sawant and Mishra, 2022</xref>). Though clinical evidence is limited to case reports (<xref ref-type="bibr" rid="B27">Nimbalkar et al., 2024</xref>), these suggest potential for reduced chemotherapy toxicities and prolonged disease-free intervals in breast cancer patients (<xref ref-type="bibr" rid="B27">Nimbalkar et al., 2024</xref>).</p>
</sec>
<sec id="s8">
<label>8</label>
<title>Limitations and future directions</title>
<sec id="s8-1">
<label>8.1</label>
<title>Evidence-level classification and critical perspective</title>
<p>A critical appraisal of <italic>Abhraka Bhasma</italic>, using an adapted evidence-grading framework, classifies the entire body of evidence as low-level. Current data is restricted to Level 5 (preclinical) evidence and Level 4 (case reports) (<xref ref-type="bibr" rid="B27">Nimbalkar et al., 2024</xref>; <xref ref-type="bibr" rid="B3">Bendale et al., 2022</xref>) which is limited and serve only for hypothesis generation and are not definitive proof of therapeutic efficacy due to their uncontrolled nature. Crucially, high-level Level 1&#x2013;3 evidence, particularly randomized controlled trials (RCTs), is completely absent. The primary limitation in the field is the significant gap between preclinical promise and clinical validation. Therefore, it is not ready for clinical recommendation and the efficacy of <italic>Abhraka Bhasma</italic> in cancer remains exploratory which highlights an urgent need for well-designed clinical trials before it can be considered for integration into evidence-based oncology.</p>
</sec>
<sec id="s8-2">
<label>8.2</label>
<title>Safety in women&#x2019;s health and medical supervision</title>
<p>The safety profile of <italic>Abhraka Bhasma</italic> especially in women&#x2019;s health is a critical consideration. No systematic studies have been conducted yet to assess the safety of <italic>Abhraka Bhasma</italic> during pregnancy and lactation and this leads to a significant knowledge gap. Heavy-metal accumulation and its unknown effects on fetal or neonatal health give rise to risks of unknown magnitude. Until comprehensive reproductive toxicity studies establish its safety, its use must be contraindicated in pregnant and lactating women. This precaution aligns with global pharmacological standards and helps ensure that therapeutic exploration does not inadvertently compromise maternal or neonatal health. Though we have encouraging preclinical findings, it is essential to have a clear boundary between these findings and clinical application. Self-medication, inappropriate dosing, or unsupervised chronic use creates significant safety concerns, including toxicity. Therefore, the use of <italic>Abhraka Bhasma</italic> must remain restricted to controlled therapeutic contexts under the strict guidance of trained healthcare professionals until comprehensive clinical safety data and standardized dosing regimens are available.</p>
</sec>
<sec id="s8-3">
<label>8.3</label>
<title>Future scope</title>
<p>Current findings on <italic>Abhraka Bhasma</italic> in breast cancer care are promising, but they are primarily preclinical. To bridge the gap between traditional use and evidence based clinical application, a structured and systematic research pathway is essential.</p>
<p>Randomized controlled trials assessing the adjunct role of <italic>Abhraka Bhasma</italic> to conventional therapies in enhancing quality of life, improving survival and reducing treatment toxicities is needed.</p>
<p>Mechanistic studies exploring molecular pathways must be pursued. Elucidating its pharmacological actions is critical to fill the gap between traditional Ayurvedic knowledge and modern oncology frameworks. Furthermore, collaborative research integrating Nanotechnology (for pharmaceutical standardization), Pharmacology (for mechanistic validation), <italic>Ayurveda</italic> (for clinical context) and Oncology (for rigorous trial design) opens new frontiers in cancer therapeutics.</p>
</sec>
</sec>
<sec sec-type="conclusion" id="s9">
<label>9</label>
<title>Conclusion</title>
<p>
<italic>Abhraka Bhasma</italic> (Mica Nanoparticles) offers a unique bridge between holistic framework of Ayurveda and specific pathways of modern cancer biology, which exemplifies its integrative relevance. The traditional use of the formulation as a <italic>rasayana</italic> (rejuvenator) and <italic>ojovardhaka</italic> (immune-enhancer) correlates strongly with modern preclinical findings of cytoprotection, immunomodulation and DNA repair. This suggests its valuable complementary strategy to mitigate the toxicities of conventional treatments and enhance therapeutic outcomes.</p>
<p>Eventhough the preclinical findings are promising a significant gap in mechanistic and clinical validation prevents its translation into evidence-based care. When used as an alternative treatment in breast cancer patients, critically, there is a complete absence of randomized controlled trials to validate its safety, efficacy, and potential drug interactions.</p>
<p>This gap emphazises the necessity of a responsible translational outlook. While preclinical data affirm <italic>Abhraka Bhasma</italic>&#x2019;s biological promise, rigorous standardization and toxicity profiling, randomized trials are essential before clinical translation. These steps are essential before this ancient nanomedicine can be safely and effectively integrated into a modern oncology setting.</p>
</sec>
</body>
<back>
<sec sec-type="author-contributions" id="s10">
<title>Author contributions</title>
<p>DS: Writing &#x2013; original draft. AK: Writing &#x2013; original draft, Software.</p>
</sec>
<sec sec-type="COI-statement" id="s12">
<title>Conflict of interest</title>
<p>The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="ai-statement" id="s13">
<title>Generative AI statement</title>
<p>The author(s) declared that generative AI was not used in the creation of this manuscript.</p>
<p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p>
</sec>
<sec sec-type="disclaimer" id="s14">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<fn-group>
<fn fn-type="custom" custom-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/439467/overview">Javier Echeverria</ext-link>, University of Santiago, Chile</p>
</fn>
<fn fn-type="custom" custom-type="reviewed-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1287549/overview">Vivek P. Chavda</ext-link>, L M College of Pharmacy, India</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/2389884/overview">Omowumi Adewale</ext-link>, Osun State University, Nigeria</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/3159723/overview">Thi Phuong Nhung Tran</ext-link>, Industrial University of Ho Chi Minh City, Vietnam</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="B1">
<mixed-citation publication-type="book">
<person-group person-group-type="editor">
<name>
<surname>Acharya</surname>
<given-names>Y. T.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Rasaratna samuccaya</article-title>. <edition>1st ed.</edition> (<publisher-loc>Varanasi</publisher-loc>: <publisher-name>Chaukhambha Sanskrit Bhawan</publisher-name>), <fpage>68</fpage>&#x2013;<lpage>72</lpage>.</mixed-citation>
</ref>
<ref id="B2">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Balkrishna</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sinha</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Varshney</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2025</year>). <article-title>Calcio-herbal medicine divya-swasari-vati demonstrates acceptable non-clinical safety profile in the repeated-dose 28-day subacute oral toxicity study in sprague-dawley rats, under GLP compliance</article-title>. <source>Front. Pharmacol.</source> <volume>16</volume>, <fpage>1547532</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2025.1547532</pub-id>
<pub-id pub-id-type="pmid">40599800</pub-id>
</mixed-citation>
</ref>
<ref id="B3">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bendale</surname>
<given-names>Y. N.</given-names>
</name>
<name>
<surname>Kadam</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Patil</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Birari&#x2010;Gawande</surname>
<given-names>P. K.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Complete tumor regression with exclusive ayurvedic rasayana regimen in high&#x2010;grade diffuse large b&#x2010;cell lymphoma: a case report</article-title>. <source>Clin. Case Rep.</source> <volume>10</volume> (<issue>4</issue>), <fpage>e05696</fpage>. <pub-id pub-id-type="doi">10.1002/ccr3.5696</pub-id>
<pub-id pub-id-type="pmid">35441028</pub-id>
</mixed-citation>
</ref>
<ref id="B4">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bengal</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ramteke</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Belge</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Mane</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Firdaus</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Role of abhrak bhasma as rasayan aushadi with special reference to anti-ageing properties</article-title>. <source>World J. Pharm. Res.</source> <volume>9</volume> (<issue>7</issue>), <fpage>7</fpage>&#x2013;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.20959/wjpr20207-17969</pub-id>
</mixed-citation>
</ref>
<ref id="B5">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bhatia</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Kale</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Analytical evaluation of an ayurvedic formulation - abhraka bhasma</article-title>. <source>Int. J. Pharm. Sci. Rev. Res.</source> <volume>23</volume> (<issue>1</issue>), <fpage>17</fpage>&#x2013;<lpage>23</lpage>.</mixed-citation>
</ref>
<ref id="B6">
<mixed-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Charaka</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2009</year>). in <source>Charaka samhita: with chakrapani commentary, sutra sthana, chapters 1 and 20</source>. Editor <person-group person-group-type="editor">
<name>
<surname>Sharma</surname>
<given-names>P.</given-names>
</name>
</person-group> <edition>1st ed</edition> (<publisher-loc>Varanasi</publisher-loc>: <publisher-name>Chaukhambha Orientalia</publisher-name>), <fpage>116</fpage>&#x2013;<lpage>123</lpage>.</mixed-citation>
</ref>
<ref id="B7">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chatterjee</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ghosh</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Roy</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2024</year>). <article-title>Application of ayurvedic bhasma for the treatment of cancer. Indian J ayurveda integr</article-title>. <source>Med. KLEU</source> <volume>5</volume> (<issue>1</issue>), <fpage>3</fpage>&#x2013;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.4103/ijaim.ijaim_61_23</pub-id>
</mixed-citation>
</ref>
<ref id="B8">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cho</surname>
<given-names>S. Y.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>H. J.</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>S. M.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Jung</surname>
<given-names>Y. K.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>S. H.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Particled mica STB-HO has chemopreventive potential <italic>via</italic> G1 arrest and inhibition of proliferation and vascular endothelial growth factor receptor 2 in HCT116 colorectal cancer cells</article-title>. <source>BMC Complement. Altern. Med.</source> <volume>13</volume>, <fpage>189</fpage>. <pub-id pub-id-type="doi">10.1186/1472-6882-13-189</pub-id>
<pub-id pub-id-type="pmid">23883349</pub-id>
</mixed-citation>
</ref>
<ref id="B9">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Choi</surname>
<given-names>S. W.</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>T. H.</given-names>
</name>
<name>
<surname>Uddin</surname>
<given-names>M. H.</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>J. H.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>T. W.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>B. C.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>STB-HO, a novel mica fine particle, inhibits the teratoma-forming ability of human embryonic stem cells after <italic>in vivo</italic> transplantation</article-title>. <source>Oncotarget</source> <volume>7</volume> (<issue>3</issue>), <fpage>2684</fpage>&#x2013;<lpage>2695</lpage>. <pub-id pub-id-type="doi">10.18632/oncotarget.6782</pub-id>
<pub-id pub-id-type="pmid">26646796</pub-id>
</mixed-citation>
</ref>
<ref id="B10">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coleman</surname>
<given-names>F. J.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>Nitric oxide in immunity and inflammation</article-title>. <source>Int. Immunopharmacol.</source> <volume>1</volume> (<issue>8</issue>), <fpage>1397</fpage>&#x2013;<lpage>1406</lpage>. <pub-id pub-id-type="doi">10.1016/s1567-5769(01)00086-8</pub-id>
<pub-id pub-id-type="pmid">11515807</pub-id>
</mixed-citation>
</ref>
<ref id="B11">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duranova</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Kuzelova</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Borotova</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Simora</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Fialkova</surname>
<given-names>V.</given-names>
</name>
</person-group> (<year>2024</year>). <article-title>Human umbilical vein endothelial cells as a versatile cellular model system in diverse experimental paradigms: an ultrastructural perspective</article-title>. <source>Microsc. Microanal.</source> <volume>30</volume> (<issue>3</issue>), <fpage>419</fpage>&#x2013;<lpage>439</lpage>. <pub-id pub-id-type="doi">10.1093/mam/ozae048</pub-id>
<pub-id pub-id-type="pmid">38817111</pub-id>
</mixed-citation>
</ref>
<ref id="B12">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ebihara</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Urashima</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Amano</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Yamamura</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Konishi</surname>
<given-names>N.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Macrophage polarization toward M1 phenotype in T cell transfer colitis model</article-title>. <source>BMC Gastroenterol.</source> <volume>23</volume>, <fpage>411</fpage>. <pub-id pub-id-type="doi">10.1186/s12876-023-03054-1</pub-id>
<pub-id pub-id-type="pmid">38012544</pub-id>
</mixed-citation>
</ref>
<ref id="B13">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gavrilas</surname>
<given-names>L. I.</given-names>
</name>
<name>
<surname>Cruceriu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Ionescu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Miere</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Balacescu</surname>
<given-names>O.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Pro-apoptotic genes as new targets for single and combinatorial treatments with resveratrol and curcumin in colorectal cancer</article-title>. <source>Food Funct.</source> <volume>10</volume> (<issue>6</issue>), <fpage>3717</fpage>&#x2013;<lpage>3726</lpage>. <pub-id pub-id-type="doi">10.1039/c9fo01014a</pub-id>
<pub-id pub-id-type="pmid">31169275</pub-id>
</mixed-citation>
</ref>
<ref id="B14">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gopinath</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Shivashankar</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>A study on toxicity and anti-hyperglycemic effects of abhrak bhasma in rats, J ayurveda integr</article-title>. <source>Med</source> <volume>12</volume> (<issue>3</issue>), <fpage>443</fpage>&#x2013;<lpage>451</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaim.2021.03.004</pub-id>
<pub-id pub-id-type="pmid">34362606</pub-id>
</mixed-citation>
</ref>
<ref id="B15">
<mixed-citation publication-type="book">
<collab>Government of India</collab> (<year>2003</year>). <source>The ayurvedic formulary of India</source>. <edition>2nd ed.</edition> <publisher-loc>New Delhi</publisher-loc>: <publisher-name>Ministry of AYUSH</publisher-name>, <fpage>247</fpage>&#x2013;<lpage>249</lpage>.</mixed-citation>
</ref>
<ref id="B16">
<mixed-citation publication-type="book">
<collab>International Council for Harmonisation (ICH)</collab> (<year>2022</year>). <source>ICH harmonised guideline: guideline for elemental impurities Q3D(R2)</source>. <publisher-loc>Geneva, Switzerland</publisher-loc>: <publisher-name>ICH</publisher-name>.</mixed-citation>
</ref>
<ref id="B17">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jani</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Bedarkar</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Patgiri</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>A comprehensive review on formulations containing abhraka bhasma</article-title>. <source>J. Indian Syst. Med.</source> <volume>9</volume> (<issue>2</issue>), <fpage>69</fpage>&#x2013;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.4103/jism.jism_34_21</pub-id>
</mixed-citation>
</ref>
<ref id="B18">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jourdan</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>R&#xe8;me</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Goldschmidt</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Fiol</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Pantesco</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>De Vos</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2009</year>). <article-title>Gene expression of anti- and pro-apoptotic proteins in malignant and normal plasma cells</article-title>. <source>Br. J. Haematol.</source> <volume>145</volume> (<issue>1</issue>), <fpage>45</fpage>&#x2013;<lpage>58</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2141.2008.07562.x</pub-id>
<pub-id pub-id-type="pmid">19183193</pub-id>
</mixed-citation>
</ref>
<ref id="B19">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kang</surname>
<given-names>T. W.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>H. S.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>B. C.</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>T. H.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>S. W.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>Y. J.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Mica nanoparticle STB-HO eliminates human breast carcinoma cells by regulating the interaction of tumor with its immune microenvironment</article-title>. <source>Sci. Rep.</source> <volume>5</volume>, <fpage>17515</fpage>. <pub-id pub-id-type="doi">10.1038/srep17515</pub-id>
<pub-id pub-id-type="pmid">26631982</pub-id>
</mixed-citation>
</ref>
<ref id="B20">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kantak</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Rajurkar</surname>
<given-names>N.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Bio-accessibility of pre-synthesized abhrak, naga and tamra bhasma</article-title>. <source>J. ISAS</source> <volume>1</volume> (<issue>4</issue>), <fpage>25</fpage>&#x2013;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.59143/isas.jisas.1.4.ORPO1427</pub-id>
</mixed-citation>
</ref>
<ref id="B21">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kantak</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Rajurkar</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Adhyapak</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Synthesis and characterization of abhraka (mica) bhasma by two different methods</article-title>. <source>J. Ayurveda Integr. Med.</source> <volume>11</volume> (<issue>3</issue>), <fpage>236</fpage>&#x2013;<lpage>242</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaim.2018.11.003</pub-id>
<pub-id pub-id-type="pmid">30826258</pub-id>
</mixed-citation>
</ref>
<ref id="B22">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuchewar</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Borkar</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Nisargandha</surname>
<given-names>M. A.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Evaluation of antioxidant potential of rasayana drugs in healthy human volunteers</article-title>. <source>Ayu</source> <volume>35</volume> (<issue>1</issue>), <fpage>46</fpage>&#x2013;<lpage>49</lpage>. <pub-id pub-id-type="doi">10.4103/0974-8520.141919</pub-id>
<pub-id pub-id-type="pmid">25364199</pub-id>
</mixed-citation>
</ref>
<ref id="B23">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kulala</surname>
<given-names>D. S.</given-names>
</name>
<name>
<surname>Prasad</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Reddy</surname>
<given-names>P. S.</given-names>
</name>
<name>
<surname>Maruthiyodan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Joshi</surname>
<given-names>M. B.</given-names>
</name>
<name>
<surname>Satyamoorthy</surname>
<given-names>K.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Understanding the effects of abhraka bhasma on genotoxicity and its DNA repair potential in mouse model</article-title>. <source>J. Ayurveda Integr. Med.</source> <volume>14</volume> (<issue>2</issue>), <fpage>100598</fpage>. <pub-id pub-id-type="doi">10.1016/j.jaim.2022.100598</pub-id>
<pub-id pub-id-type="pmid">35973910</pub-id>
</mixed-citation>
</ref>
<ref id="B24">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kulkarni</surname>
<given-names>A. N.</given-names>
</name>
<name>
<surname>Mohan</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Patil</surname>
<given-names>P. S.</given-names>
</name>
<name>
<surname>Wagh</surname>
<given-names>M. D.</given-names>
</name>
<name>
<surname>Pande</surname>
<given-names>S. P.</given-names>
</name>
<name>
<surname>Kulkarni</surname>
<given-names>R. A.</given-names>
</name>
</person-group> (<year>2024</year>). <article-title>Safety assessment of ayurvedic gold medication suvarna bhasma, in wistar rats</article-title>. <source>Indian Drugs</source> <volume>61</volume> (<issue>04</issue>), <fpage>65</fpage>&#x2013;<lpage>71</lpage>. <pub-id pub-id-type="doi">10.53879/id.61.04.14066</pub-id>
</mixed-citation>
</ref>
<ref id="B25">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>A. V.</given-names>
</name>
<name>
<surname>Oesterreich</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Davidson</surname>
<given-names>N. E.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>MCF-7 cells--changing the course of breast cancer research and care for 45 years</article-title>. <source>J. Natl. Cancer Inst.</source> <volume>107</volume> (<issue>7</issue>), <fpage>djv073</fpage>. <pub-id pub-id-type="doi">10.1093/jnci/djv073</pub-id>
<pub-id pub-id-type="pmid">25828948</pub-id>
</mixed-citation>
</ref>
<ref id="B26">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lepoivre</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Chenais</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Yapo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lemaire</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Thelander</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Tenu</surname>
<given-names>J. P.</given-names>
</name>
</person-group> (<year>1990</year>). <article-title>Alterations of ribonucleotide reductase activity following induction of the nitrite-generating pathway in adenocarcinoma cells</article-title>. <source>J. Biol. Chem.</source> <volume>265</volume> (<issue>24</issue>), <fpage>14143</fpage>&#x2013;<lpage>14149</lpage>. <pub-id pub-id-type="doi">10.1016/s0021-9258(18)77279-7</pub-id>
<pub-id pub-id-type="pmid">2117605</pub-id>
</mixed-citation>
</ref>
<ref id="B27">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nimbalkar</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Baheti</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Pawar</surname>
<given-names>A. T.</given-names>
</name>
<name>
<surname>Tagalpallewar</surname>
<given-names>A. A.</given-names>
</name>
<name>
<surname>Nimbalkar</surname>
<given-names>M. R.</given-names>
</name>
</person-group> (<year>2024</year>). <article-title>Eleven years of disease free survival in a case of invasive ductal carcinoma (IDC) Rt breast grade 3, stage 3, treated with add on ayurveda treatment: a casereport</article-title>. <source>J. Ayurveda Integr. Med.</source> <volume>15</volume> (<issue>1</issue>), <fpage>100881</fpage>. <pub-id pub-id-type="doi">10.1016/j.jaim.2023.100881</pub-id>
<pub-id pub-id-type="pmid">38306823</pub-id>
</mixed-citation>
</ref>
<ref id="B28">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pandey</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Bedarkar</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Patgiri</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Pharmaceutical standardisation of abhraka bhasma amrutikarana</article-title>. <source>Int. J. Ayurveda Integr. Med.</source> <volume>3</volume> (<issue>1</issue>). <pub-id pub-id-type="doi">10.51649/healer.101</pub-id>
</mixed-citation>
</ref>
<ref id="B29">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pandit</surname>
<given-names>V. A.</given-names>
</name>
<name>
<surname>Singhal</surname>
<given-names>S. K.</given-names>
</name>
<name>
<surname>Deshmane</surname>
<given-names>G. B.</given-names>
</name>
<name>
<surname>Sahasrabuddhe</surname>
<given-names>R. A.</given-names>
</name>
<name>
<surname>Karandikar</surname>
<given-names>M. N.</given-names>
</name>
<name>
<surname>Pawar</surname>
<given-names>M. S.</given-names>
</name>
<etal/>
</person-group> (<year>2024</year>). <article-title>Toxicity profile of standardized krishna vajra abhraka bhasma made from biotite mica</article-title>. <source>J. Ayurveda Integr. Med.</source> <volume>15</volume> (<issue>6</issue>), <fpage>100980</fpage>. <pub-id pub-id-type="doi">10.1016/j.jaim.2024.100980</pub-id>
<pub-id pub-id-type="pmid">39616794</pub-id>
</mixed-citation>
</ref>
<ref id="B30">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname>
<given-names>S. J.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>Y. Y.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>J. Y.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>S. W.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ku</surname>
<given-names>S. Y.</given-names>
</name>
</person-group> (<year>2024</year>). <article-title>Advancements in human embryonic stem cell research: clinical applications and ethical issues</article-title>. <source>Tissue Eng. Regen. Med.</source> <volume>21</volume> (<issue>3</issue>), <fpage>379</fpage>&#x2013;<lpage>394</lpage>. <pub-id pub-id-type="doi">10.1007/s13770-024-00627-3</pub-id>
<pub-id pub-id-type="pmid">38502279</pub-id>
</mixed-citation>
</ref>
<ref id="B31">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prasetiyo</surname>
<given-names>P. D.</given-names>
</name>
<name>
<surname>Wahjoepramono</surname>
<given-names>E. J.</given-names>
</name>
</person-group> (<year>2024</year>). <article-title>Vascular endothelial growth factor receptor 2 (VEGFR2) rs2071559 gene polymorphism and the risk of gliomas: a systematic review and meta-Analysis</article-title>. <source>J. Clin. Med.</source> <volume>13</volume> (<issue>15</issue>), <fpage>4332</fpage>. <pub-id pub-id-type="doi">10.3390/jcm13154332</pub-id>
<pub-id pub-id-type="pmid">39124599</pub-id>
</mixed-citation>
</ref>
<ref id="B32">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rajput</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>San Martin</surname>
<given-names>I. D.</given-names>
</name>
<name>
<surname>Rose</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Beko</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Levea</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Sharratt</surname>
<given-names>E.</given-names>
</name>
<etal/>
</person-group> (<year>2008</year>). <article-title>Characterization of HCT116 human Colon cancer cells in an orthotopic model</article-title>. <source>J. Surg. Res.</source> <volume>147</volume> (<issue>2</issue>), <fpage>276</fpage>&#x2013;<lpage>281</lpage>. <pub-id pub-id-type="doi">10.1016/j.jss.2007.04.021</pub-id>
<pub-id pub-id-type="pmid">17961596</pub-id>
</mixed-citation>
</ref>
<ref id="B33">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sawant</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Mishra</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Lekhan karma of haridra w.s.r. to obesity - Pilot study</article-title>. <source>J. Ayurveda Integr. Med. Sci.</source> <volume>7</volume> (<issue>1</issue>).</mixed-citation>
</ref>
<ref id="B34">
<mixed-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Sen</surname>
<given-names>G. D.</given-names>
</name>
</person-group> (<year>2005</year>). <source>Bhaishajya ratnavali (vaidya j&#x12b;vana), Arbuda chikitsa adhyaya (chapter 49)</source>. <edition>1st ed.</edition> <publisher-loc>Varanasi</publisher-loc>: <publisher-name>Chaukhambha Sanskrit Bhawan</publisher-name>, <fpage>841</fpage>&#x2013;<lpage>850</lpage>.</mixed-citation>
</ref>
<ref id="B35">
<mixed-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Sharma</surname>
<given-names>S. N.</given-names>
</name>
</person-group> (<year>2004</year>). <source>Rasa tarangini</source>. <edition>11th ed.</edition> <publisher-loc>New Delhi</publisher-loc>: <publisher-name>Motilal Banarsidass</publisher-name>, <fpage>466</fpage>&#x2013;<lpage>495</lpage>.</mixed-citation>
</ref>
<ref id="B36">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sharma</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Martins</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Kuca</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Chaudhary</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kabra</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rao</surname>
<given-names>M. M.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Chyawanprash: a traditional Indian bioactive health supplement</article-title>. <source>Biomolecules</source> <volume>9</volume> (<issue>5</issue>), <fpage>161</fpage>. <pub-id pub-id-type="doi">10.3390/biom9050161</pub-id>
<pub-id pub-id-type="pmid">31035513</pub-id>
</mixed-citation>
</ref>
<ref id="B37">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sreelakshmi</surname>
<given-names>K. S.</given-names>
</name>
<name>
<surname>Nandagopalan</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2024</year>). <article-title>Anticancer and immunomodulatory properties of herbomineral formulation abhrak Bhasma on breast cancer</article-title>. <source>Indian J. Pharm. Sci.</source> <volume>86</volume> (<issue>5</issue>), <fpage>1621</fpage>&#x2013;<lpage>1627</lpage>. <pub-id pub-id-type="doi">10.36468/pharmaceutical-sciences.1429</pub-id>
</mixed-citation>
</ref>
<ref id="B38">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Subedi</surname>
<given-names>R. P.</given-names>
</name>
<name>
<surname>Vartak</surname>
<given-names>R. R.</given-names>
</name>
<name>
<surname>Kale</surname>
<given-names>P. G.</given-names>
</name>
</person-group> (<year>2018a</year>). <article-title>Modulation of oxidative stress by abhrak bhasma in Drosophila melanogaster</article-title>. <source>Asian J. Pharm. Clin. Res.</source> <volume>11</volume> (<issue>5</issue>), <fpage>130</fpage>&#x2013;<lpage>134</lpage>. <pub-id pub-id-type="doi">10.22159/ajpcr.2018.v11i5.24472</pub-id>
</mixed-citation>
</ref>
<ref id="B39">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Subedi</surname>
<given-names>R. P.</given-names>
</name>
<name>
<surname>Vartak</surname>
<given-names>R. R.</given-names>
</name>
<name>
<surname>Kale</surname>
<given-names>P. G.</given-names>
</name>
</person-group> (<year>2018b</year>). <article-title>Management of heat stress in Drosophila melanogaster with abhrak bhasma and ascorbic acid as antioxidant supplements</article-title>. <source>J. Appl. Biol. Biotechnol.</source> <volume>6</volume> (<issue>2</issue>), <fpage>31</fpage>&#x2013;<lpage>35</lpage>. <pub-id pub-id-type="doi">10.7324/JABB.2018.60204</pub-id>
</mixed-citation>
</ref>
<ref id="B40">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sung</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ferlay</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Siegel</surname>
<given-names>R. L.</given-names>
</name>
<name>
<surname>Laversanne</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Soerjomataram</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Jemal</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title>. <source>CA Cancer J. Clin.</source> <volume>71</volume> (<issue>3</issue>), <fpage>209</fpage>&#x2013;<lpage>249</lpage>. <pub-id pub-id-type="doi">10.3322/caac.21660</pub-id>
<pub-id pub-id-type="pmid">33538338</pub-id>
</mixed-citation>
</ref>
<ref id="B41">
<mixed-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Sushruta</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Sushruta Samhita: with Nibandha Sangraha Commentary, Nidana Sthana</article-title>. Acharya J. T. Editor. <edition>1st ed</edition> (<publisher-loc>Varanasi</publisher-loc>: <publisher-name>Chaukhambha Surbharati Prakashan</publisher-name>), <comment>297&#x2013;305, 297&#x2013;305</comment>, <fpage>297</fpage>&#x2013;<lpage>300</lpage>.</mixed-citation>
</ref>
<ref id="B42">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taciak</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Bia&#x142;asek</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Braniewska</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Sas</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Sawicka</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Kiraga</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Evaluation of phenotypic and functional stability of RAW 264.7 cell line through serial passages</article-title>. <source>PLoS One</source> <volume>13</volume> (<issue>6</issue>), <fpage>e0198943</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0198943</pub-id>
<pub-id pub-id-type="pmid">29889899</pub-id>
</mixed-citation>
</ref>
<ref id="B43">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tamhankar</surname>
<given-names>Y. L.</given-names>
</name>
<name>
<surname>Gharote</surname>
<given-names>A. P.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Effect of puta on <italic>in vitro</italic> anticancer activity of shataputi abhraka bhasma on lung, leukemia and prostate cancer cell lines</article-title>. <source>J. Ayurveda Integr. Med.</source> <volume>11</volume>, <fpage>118</fpage>&#x2013;<lpage>123</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaim.2017.07.007</pub-id>
<pub-id pub-id-type="pmid">30391122</pub-id>
</mixed-citation>
</ref>
<ref id="B44">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tau</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Rothman</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>Biologic functions of the IFN&#x2010;&#x3b3; receptors</article-title>. <source>Allergy</source> <volume>54</volume> (<issue>12</issue>), <fpage>1233</fpage>&#x2013;<lpage>1251</lpage>. <pub-id pub-id-type="doi">10.1034/j.1398-9995.1999.00099.x</pub-id>
<pub-id pub-id-type="pmid">10688427</pub-id>
</mixed-citation>
</ref>
<ref id="B45">
<mixed-citation publication-type="book">
<person-group person-group-type="editor">
<name>
<surname>Tripathi</surname>
<given-names>I.</given-names>
</name>
</person-group> (<year>2005</year>). <source>Yogaratnakara: granthi&#x2013;arbuda chikitsa adhyaya</source>. <edition>1st ed.</edition> (<publisher-loc>Varanasi</publisher-loc>: <publisher-name>Chaukhambha Sanskrit Sansthan</publisher-name>), <fpage>531</fpage>&#x2013;<lpage>540</lpage>.</mixed-citation>
</ref>
<ref id="B46">
<mixed-citation publication-type="book">
<person-group person-group-type="author">
<name>
<surname>Vagbhata</surname>
<given-names>V.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Ashtanga Hridaya: with Sarvangasundara Commentary, Sutra Sthana, Chapter 1</article-title>. Murthy K. R. S., editor. <edition>1st ed.</edition> (<publisher-loc>Varanasi</publisher-loc>: <publisher-name>Chaukhambha Krishnadas Academy</publisher-name>) <comment>3&#x2013;6, 106&#x2013;111</comment>, <fpage>94</fpage>&#x2013;<lpage>98</lpage>.</mixed-citation>
</ref>
<ref id="B47">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Van Meerloo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kaspers</surname>
<given-names>G. J.</given-names>
</name>
<name>
<surname>Cloos</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Cell sensitivity assays: the MTT assay</article-title>. <source>Methods Mol. Biol.</source> <volume>731</volume>, <fpage>237</fpage>&#x2013;<lpage>245</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-61779-080-5_20</pub-id>
<pub-id pub-id-type="pmid">21516412</pub-id>
</mixed-citation>
</ref>
<ref id="B48">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wele</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>De</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Dalvi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Devi</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Pandit</surname>
<given-names>V.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Nanoparticles of biotite mica as krishna vajra abhraka bhasma: synthesis and characterization</article-title>. <source>J. Ayurveda Integr. Med.</source> <volume>12</volume> (<issue>2</issue>), <fpage>269</fpage>&#x2013;<lpage>282</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaim.2020.09.004</pub-id>
<pub-id pub-id-type="pmid">33402266</pub-id>
</mixed-citation>
</ref>
<ref id="B49">
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zafar</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Khatoon</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>M. J.</given-names>
</name>
<name>
<surname>Abu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Naeem</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2025</year>). <article-title>Advancements and limitations in traditional anti-cancer therapies: a comprehensive review of surgery, chemotherapy, radiation therapy, and hormonal therapy</article-title>. <source>Discov. Oncol.</source> <volume>151</volume> (<issue>16</issue>), <fpage>607</fpage>. <pub-id pub-id-type="doi">10.1007/s12672-025-02198-8</pub-id>
<pub-id pub-id-type="pmid">40272602</pub-id>
</mixed-citation>
</ref>
</ref-list>
</back>
</article>